In order to prevent the COVID-19 epidemic from spreading more widely in China, China gave residents free COVID-19 vaccine, but there are several COVID-19 vaccines on the market, and many people don't know much about these COVID-19 vaccines. So, which company is Beijing Bio-COVID-19 Vaccine? Beijing Bio-COVID-19 Vaccine Which company's Beijing Bio-vaccine is produced by Sinopharm Group China Bio-Beijing Institute of Biological Products Co., Ltd. (Beijing Institute)? In other words, Beijing Bio-COVID-19 vaccine is a traditional Chinese medicine. Introduction of Beijing Biological COVID-19 Vaccine 1. The commercial name of Beijing Bio-COVID-19 vaccine is Zhongaikewei, and the English name is coronavirus pneumonia-19 vaccine (Vero Cell), which is inactivated. 2. The main active ingredient of Jing Bio COVID-19 vaccine is inactivated novel coronavirus strain 19nCoV-CDC-Tan-HB02, the adjuvant is aluminum hydroxide adjuvant, and the auxiliary materials are disodium hydrogen phosphate, sodium chloride and sodium dihydrogen phosphate. 3. Beijing Bio-COVID-19 Vaccine is targeted at people aged 65,438+08 and above, which has a certain protective effect on people aged 65,438+08-59. According to the existing clinical trial data, people aged 60 and above have produced neutralizing antibodies to a certain extent after being vaccinated with this product. 4. The effective rate of Beijing Bio-COVID-19 vaccine JAMA published the detailed mid-term clinical analysis data of two inactivated COVID-19 vaccines of Sinopharm Zhongsheng Group in Beijing and Wuhan online, and the effective rate of Sinopharm Zhongsheng Beijing COVID-19 vaccine was 78. 1%. How to Choose COVID-19 Vaccine and Kexing As far as the process route is concerned, both vaccines are inactivated virus vaccines. From the clinical data obtained in the first, second and third clinical stages, they all meet the requirements of the US Food and Drug Administration. According to phase III clinical data, the protection rate of one is 79.34% and the other is 72.5 1%, both of which are better than the protection rate of more than 50% required by the World Health Organization. The positive conversion rate of neutralizing antibodies of the two vaccines is close to 100%, and the severe protection rate can also reach 100%. Therefore, from the data of effectiveness and safety, the choice of these two vaccines is equally important. In order to prevent the COVID-19 epidemic from spreading more widely in China, China gave residents free COVID-19 vaccine, but there are several COVID-19 vaccines on the market, and many people don't know much about these COVID-19 vaccines. So, which company is Beijing Bio-COVID-19 Vaccine? Beijing Bio-COVID-19 Vaccine Which company's Beijing Bio-vaccine is produced by Sinopharm Group China Bio-Beijing Institute of Biological Products Co., Ltd. (Beijing Institute)? In other words, Beijing Bio-COVID-19 vaccine is a traditional Chinese medicine. Introduction of Beijing Biological COVID-19 Vaccine 1. The commercial name of Beijing Bio-COVID-19 vaccine is Zhongaikewei, and the English name is coronavirus pneumonia-19 vaccine (Vero Cell), which is inactivated. 2. The main active ingredient of Jing Bio COVID-19 vaccine is inactivated novel coronavirus strain 19nCoV-CDC-Tan-HB02, the adjuvant is aluminum hydroxide adjuvant, and the auxiliary materials are disodium hydrogen phosphate, sodium chloride and sodium dihydrogen phosphate. 3. Beijing Bio-COVID-19 Vaccine is targeted at people aged 65,438+08 and above, which has a certain protective effect on people aged 65,438+08-59. According to the existing clinical trial data, people aged 60 and above have produced neutralizing antibodies to a certain extent after being vaccinated with this product. 4. The effective rate of Beijing Bio-COVID-19 vaccine JAMA published the detailed mid-term clinical analysis data of two inactivated COVID-19 vaccines of Sinopharm Zhongsheng Group in Beijing and Wuhan online, and the effective rate of Sinopharm Zhongsheng Beijing COVID-19 vaccine was 78. 1%. How to Choose COVID-19 Vaccine and Kexing As far as the process route is concerned, both vaccines are inactivated virus vaccines. From the clinical data obtained in the first, second and third clinical stages, they all meet the requirements of the US Food and Drug Administration. According to phase III clinical data, the protection rate of one is 79.34% and the other is 72.5 1%, both of which are better than the protection rate of more than 50% required by the World Health Organization. The positive conversion rate of neutralizing antibodies of the two vaccines is close to 100%, and the severe protection rate can also reach 100%. Therefore, from the data of effectiveness and safety, the choice of these two vaccines is equally important.